Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Cantargia AB ( (SE:CANTA) ) is now available.
Cantargia AB announced promising results from its CANFOUR trial, showcasing the efficacy of nadunolimab in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC). The trial demonstrated notable survival benefits, particularly in patients previously treated with pembrolizumab, suggesting nadunolimab’s potential to improve outcomes in this patient group and highlighting its manageable safety profile. These findings support further exploration of nadunolimab’s benefits, especially for non-squamous NSCLC patients who have progressed on immune checkpoint inhibitors.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based treatments for cancer. The company is primarily involved in the research and development of therapies targeting the IL1RAP protein, with a significant focus on addressing unmet medical needs in oncology.
Average Trading Volume: 2,278,629
Current Market Cap: SEK281.9M
See more data about CANTA stock on TipRanks’ Stock Analysis page.